Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 45, Issue 7, 2006, Pages 792-800

  Findling, Robert L ^a   Reed, Michael D ^b   O'Riordan, Mary Ann ^b   Demeter, Christine A ^a   Stansbrey, Robert J ^a   McNamara, Nora K ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aggression; Children; Conduct disorder; Pharmacokinetics; Quetiapine

Indexed keywords

QUETIAPINE;

ADOLESCENT; AGGRESSIVENESS; ARTICLE; BLOOD SAMPLING; CHILD; CHILD BEHAVIOR CHECKLIST; CLINICAL ARTICLE; CONDUCT DISORDER; DRUG DISPOSITION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FEMALE; FEVER; HEADACHE; HIGH RISK PATIENT; HUMAN; IRRITABILITY; MALE; NAUSEA; NOSE CONGESTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RATING SCALE; SEDATION; STOMACH PAIN; VOMITING;

AGGRESSION; ANTIPSYCHOTIC AGENTS; BEHAVIOR; CHILD; CONDUCT DISORDER; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 33745327268     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.chi.0000219832.23849.31     Document Type: Article

References (47)

1. Achenbach TM (1991), Manual for the Child Behavior Checklist/4-18 and 1991 profile. Burlington: University of Vermont, Department of Psychiatry
2. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL, Risperidone Disruptive Behavior Study Group (2002), Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337-1346
3. Aman MG, Tassé MJ, Rojahn J, Hammer D (1996), The Nisonger CBRF: a child behavior rating form for children with developmental disabilities. Res Dev Disabil 17:41-57
4. American Psychiatric Association (2000), Diagnostic find Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association
5. Arvanitis LA, Miller BG, Group STS (1997), Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 42:233-246
6. Barnes TRE (1989), A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676
7. Borison RLA, Arvanitis LA, Miller BG (1996), ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol 16:158-169
8. Bowden CL, Grunze H, Mullen J et al. (2005), A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 66:111-121
9. Campbell M, Adams PB, Small AM et al. (1995), Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 34:445-453
10. Campbell M, Cohen IL, Small AM (1982), Drugs in aggressive behavior. J Am Acad Child Adolesc Psychiatry 21:107-117
11. Campbell M, Small AM, Green WH et al. (1984), Behavioral efficacy of haloperidol and lithium carbonate: a comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 41:650-656
12. Conners CK (1989/1990), Manual for Conners Rating Scales. North Tonawanda, NY: Multi-Health Systems
13. Corson AHBJ, Posey DJ, Stigler KA, McDougle CJ (2004), A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry 65:1531-1536
14. Croonenberghs JFJ, Findling RL, De Smedt G, Van Dongen S, Risperidone, Group DBS (2005), Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry 44:64-72
15. DelBello M, Schwiers M, Rosenberg H, Seshadri V, Wilhoit S, Strakowski S (2002), A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 41:1216-1223
16. Devane CL, Nemeroff CB (2001), Clinical pharmacokinetics of quetiapine. An atypical antipsychotic. Clin Pharmacokinet 40:509-522
17. Dunn LM, Dunn LM (1981), Peabody Picture Vocabulary Test-Revised Manual for Forms L and M. Circle Pines, MN: American Guidance Service
18. Findling R (2002), Use of quetiapine in children and adolescents. J Clin Psychiatry 63:27-31
19. Findling R, Kauffman R, Batterson J et al. (2004b), Pharmacokinetic effects of aripiprazole in children and adolescents with conduct disorder. Int Clin Psychopharmacol 7:S440
20. Findling RL, Eerdekens M, Derivan A, Lyons B, Risperidone Disruptive, Group BS (2004a), Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 161:677-684
21. Findling RL, Gracious BL, McNamara NK et al. (2001), Rapid, continuous cycling and psychiatric co-morbidity in pediatric bipolar I disorder. Bipolar Disord 3:202-210
22. Findling RL, Gracious BL, O'Riordan MA, Reed MD, Demeter C, Blumer JL (2004c), Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 14:287-294
23. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL (2000), A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 39:509-516
24. Findling RL, Schulz SC, Reed MD, Blumer JL (1998), The antipsychotics. A pediatric perspective. Pediatr Clin North Am 45:1205-1232
25. Gibaldi M, Perrier D (1982), In: Pharmacokinetics, 2nd ed. New York: Marcel Dekker
26. Greenhill LL, Solomon M, Pleak R, Ambrosini P (1985), Molindone hydrochloride treatment of hospitalized children with conduct disorder. J Clin Psychiatry 46:20-25
27. Hayden F (2001), Long-term remission of schizophrenia in an adolescent treated with quetiapine. J Child Adolesc Psychopharmacol 11:289-293
28. Kaufman J, Birmaher B, Brent D et al. (1997), Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988
29. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003), Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med 349:1157-1167
30. Kemph JP, DeVane CL, Levin GM, Jarecke R, Miller RL (1993), Treatment of aggressive children with clonidine: results of an open pilot study. J Am Acad Child Adolesc Psychiatry 32:577-581
31. Klein RG, Abikoff H, Klass E, Ganeles D, Seese LM, Pollack S (1997), Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch Gen Psychiatry 54:1073-1080
32. Malone RP, Delaney MA, Luebbert JF, Cater J, Campbell M (2000), A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry 57:649-654
33. Marchand WR, Wirth L, Simon C (2004), Quetiapine adjunctive and monotherapy for pediatric bipolar disorder: a retrospective chart review. J Child Adolesc Psychopharmacol 14:405-411
34. Martin A, Koenig K, Scahill L, Bregman J (1999), Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 9:99-107
35. McConville BJ, Arvanitis LA, Thyrum PT et al. (2000), Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 61:252-260
36. Mukaddes NM, Abali O (2003), Quetiapine treatment of children and adolescents with Tourette's disorder. J Child Adolesc Psychopharmacol 13:295-299
37. National Institute of Mental Health (1985a), Abnormal Involuntary Movement Scale (AIMS). Psychopharmacol Bull 21:1077-1080
38. National Institute of Mental Health (1985b), Clinical Global Impressions Scale. Psychopharmacol Bull 21:839-843
39. Nemeroff CB, Kinkead B, Goldstein J (2002), Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 63:5-11
40. Párraga HC, Párraga MI (2001), Quetiapine treatment in patients with Tourette syndrome. Can J Psychiatry 46:184-185
41. Shaffer D, Gould MS, Brasic J, et al. (1983), A Children's Global Assessment Scale (CGAS). Arch Gen Psychiatry 40:1228-1231
42. Shaw JA, Lewis JE, Pascal S et al. (2001), A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 11:415-424
43. Simpson GM, Angus JWS (1970), A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19
44. Small JG, Arvanitis LA, Miller BG, Link CG (1997), Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 54:549-557
45. Snyder R, Turgay A, Aman M, Binder C, Fishman S, Carroll A, The Risperidone Conduct Study Group (2002), Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41:1026-1036
46. Szigethy E, Brent S, Findling RL (1998), Quetiapine for refractory schizophrenia. J Am Acad Child Adolesc Psychiatry 37:1127-1128
47. Turgay A, Binder C, Snyder R, Fisman S (2002), Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110:e34